Mediar Therapeutics
CompanyUnited States
Mediar Therapeutics develops one asset, in phase 2 (MTX-463 in idiopathic pulmonary fibrosis). Mostly antibody acting on CCN4; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Inhibits WISP-1 to block fibrosis progression
Phase 2, Antibody, CCN4, idiopathic pulmonary fibrosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Similar companies6